(Q33960547)

30 July 2017

title

Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer (English)

1 reference

30 July 2017

Fabrice Pierre

1

1 reference

30 July 2017

Peter C Chua

2

1 reference

30 July 2017

Sean E O'Brien

3

1 reference

30 July 2017

Adam Siddiqui-Jain

4

1 reference

30 July 2017

Pauline Bourbon

5

1 reference

30 July 2017

Mustapha Haddach

6

1 reference

30 July 2017

Jerome Michaux

7

1 reference

30 July 2017

Johnny Nagasawa

8

1 reference

30 July 2017

Michael K Schwaebe

9

1 reference

30 July 2017

Eric Stefan

10

1 reference

30 July 2017

Anne Vialettes

11

1 reference

30 July 2017

Jeffrey P Whitten

12

1 reference

30 July 2017

Ta Kung Chen

13

1 reference

30 July 2017

Levan Darjania

14

1 reference

30 July 2017

Ryan Stansfield

15

1 reference

30 July 2017

Joshua Bliesath

16

1 reference

30 July 2017

Denis Drygin

17

1 reference

30 July 2017

Caroline Ho

18

1 reference

30 July 2017

May Omori

19

1 reference

30 July 2017

Chris Proffitt

20

1 reference

30 July 2017

Nicole Streiner

21

1 reference

30 July 2017

William G Rice

22

1 reference

30 July 2017

David M Ryckman

23

1 reference

30 July 2017

Kenna Anderes

24

1 reference

30 July 2017

language of work or name

1 reference

14 July 2011

1 reference

Molecular and Cellular Biochemistry

30 July 2017

published in

1 reference

30 July 2017

volume

356

1 reference

30 July 2017

issue

1-2

1 reference

30 July 2017

page(s)

37-43

1 reference

Targeting cancer with small molecule kinase inhibitors

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11010-011-0956-5

Non-oncogene addiction and the stress phenotype of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-011-0956-5

Principles of cancer therapy: oncogene and non-oncogene addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-011-0956-5

Addiction to protein kinase CK2: a common denominator of diverse cancer cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-011-0956-5

Downregulation of CK2 induces apoptosis in cancer cells--a potential approach to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-011-0956-5

Emergence of protein kinase CK2 as a key target in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-011-0956-5

The selectivity of inhibitors of protein kinase CK2: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-011-0956-5

Antitumor activity of pyridocarbazole and benzopyridoindole derivatives that inhibit protein kinase CK2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-011-0956-5

Resorufin: a lead for a new protein kinase CK2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-011-0956-5

Synthesis of new analogs of benzotriazole, benzimidazole and phthalimide--potential inhibitors of human protein kinase CK2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-011-0956-5

How druggable is protein kinase CK2?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-011-0956-5

Development and exploitation of CK2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-011-0956-5

Inhibition of protein kinase CK2 expression and activity blocks tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-011-0956-5

New protein kinase CK2 inhibitors: jumping out of the catalytic box.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-011-0956-5

Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-011-0956-5

Discovery of a potent and selective protein kinase CK2 inhibitor by high-throughput docking

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-011-0956-5

Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-011-0956-5

Structural basis of CX-4945 binding to human protein kinase CK2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-011-0956-5

CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-011-0956-5

Induction of apoptosis by antisense CK2 in human prostate cancer xenograft model.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21755459

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11010-011-0956-5

1 reference

Dimensions Publication ID

30 July 2017

1021527215

0 references

1 reference